RCH 01

Drug Profile

RCH 01

Alternative Names: DSC cell therapy - RepliCel; Hair cell replacement therapy - RepliCel; Human autologous hair follicle cells - RepliCel; RCH-01; RepliCel; RepliCel Hair-01

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator RepliCel Life Sciences
  • Developer RepliCel Life Sciences; Shiseido
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Alopecia

Most Recent Events

  • 14 Mar 2017 Final adverse events data from a phase I/II trial in Alopecia released by RepliCel
  • 23 Feb 2017 RepliCel Life Sciences completes a phase I/II trial in Alopecia in Georgia (NCT01286649)
  • 26 Sep 2016 Clinical trials in Alopecia in Japan (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top